Literature DB >> 21846674

Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections.

S Travis King, Justin B Usery, Katherine Holloway, Laura Koeth, Kerry O Cleveland, Michael S Gelfand.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21846674     DOI: 10.1093/jac/dkr343

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  4 in total

1.  Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Ashley D Hall Snyder; Brian J Werth; Poochit Nonejuie; John P McRoberts; Joe Pogliano; George Sakoulas; Juwon Yim; Nivedita Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 2.  Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia.

Authors:  Eleni P Balli; Chris A Venetis; Spiros Miyakis
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

3.  Comment on: Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections.

Authors:  Theodoros Kelesidis
Journal:  J Antimicrob Chemother       Date:  2011-11-02       Impact factor: 5.758

Review 4.  Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions.

Authors:  Elda Righi
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.